Concomitant medical products: product id: 8781, lot#: n515795002, implanted: (b)(6) 2015, product type: catheter.
Other relevant device(s) are: product id: 8781, serial/lot #: (b)(4), ubd: 23-dec-2016, udi#: (b)(4).
If information is provided in the future, a supplemental report will be issued.
|
Information was received from a foreign healthcare provider (hcp) via a distributor regarding a patient receiving gabalon (unknown concentration at an unknown dose) via an implantable infusion pump.
The indication for use was cerebral palsy.
It was reported the pump had been replaced on (b)(6) 2022 and there was no particular problem.
On (b)(6) 2022, the patient had an outpatient consultation due to a high fever and worsening spasticity.
Botulinum toxin (btx) was injected into the lower limbs.
The patient was monitored and then went home.
On (b)(6) 2022, the patient had a normal temperature and was relieved from tension.
The patient went home and would be under observation until the next refill.
On (b)(6) 2022, the patient had an outpatient consultation due to worsening spasticity.
A refill was performed and there was not an abnormal variability rate.
A roller test was performed and it seemed like the pump was working fine, but it was not clear.
The patient had tension.
A contrast study was attempted, but it was not successful so it was discontinued.
The patient went home for observation and adjustment of hospitalization.
The patient's hospitalization was re-adjusted on the (b)(6), and after they were to be hospitalized, a roller examination and contrast study would be performed again.
The adverse events were considered unrelated to the drug, programmer, and surgical procedure, and unknown if related to the catheter or pump.
The attending physician's comments indicated the cause was unknown.
Additionally, pump "up/down rotation" was reported.
This was considered unrelated to the drug, catheter, pump, and programmer, and unknown if related to the surgical procedure.
Further complications were not reported.
Additional information was received.
On (b)(6) 2022, an "scr" drug formulation was administered via lumbar puncture and was effective.
When the system was checked again via x-ray, it seemed that the pump connection was disconnected.
After conducting a ct scan, the future plans would be considered by consulting with the neurosurgery department.
|